This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsNeighbourly Pharmacy (NBLY) 주식 개요Neighbourly Pharmacy Inc. owns and operates a chain of retail pharmacies in Canada. 자세히 보기NBLY 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장1/6과거 실적0/6재무 건전성3/6배당0/6강점공정 가치 추정치보다 낮은 30.1% 에서 거래수익은 연간 9.33% 증가할 것으로 예상됩니다.위험 분석지난 3개월 동안 상당한 내부자 매도가 있었습니다.모든 위험 점검 보기NBLY Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW474,562 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA474,562 investors already sharing narrativesYour Fair ValueCA$Current PriceCA$18.5475.9% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-128m1b2016201920222025202620282031Revenue CA$1.4bEarnings CA$40.9mAdvancedSet Fair ValueView all narrativesNeighbourly Pharmacy Inc. 경쟁사CareRxSymbol: TSX:CRRXMarket cap: CA$217.1mSucroSymbol: TSXV:SUGRMarket cap: CA$259.2mNorth WestSymbol: TSX:NWCMarket cap: CA$2.5bPharmaCorp RxSymbol: TSXV:PCRXMarket cap: CA$87.0m가격 이력 및 성과Neighbourly Pharmacy 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가CA$18.5452주 최고가CA$23.0052주 최저가CA$12.05베타0.291개월 변동0.93%3개월 변동10.82%1년 변동-13.36%3년 변동n/a5년 변동n/aIPO 이후 변동-17.56%최근 뉴스 및 업데이트공고 • Aug 14Neighbourly Pharmacy Inc. Announces CFO ChangesNeighbourly Pharmacy Inc. announced the appointment of J.P. Arcand as Chief Financial Officer. Mr. Arcand is a seasoned retail finance executive with over 20 years of experience. Mr. Arcand joins Neighbourly from Helly Hansen, a leading designer and retailer of sports apparel owned by Canadian Tire Corporation, where he most recently served as CFO in Norway, overseeing its global operations across 40 countries and multiple channels. At Neighbourly, Mr. Arcand will oversee all aspects of Neighbourly's financial operations, including financial planning and analysis, accounting, and treasury functions. He will work closely with the rest of the executive team to support Neighbourly's long-term growth objectives. Mr. Arcand succeeds Billy Wong who is leaving Neighbourly for another opportunity. Mr. Arcand will be starting at Neighbourly effective August 19, 2024.공고 • Mar 23Neighbourly Pharmacy Inc. COM to Be Deleted from OTC EquityNeighbourly Pharmacy Inc. COM (Canada) will be deleted from OTC Equity effective March 22, 2024, due to Acquisition /Merger /Amalgamation.공고 • Mar 21+ 1 more updateNeighbourly Closes Go-Private Deal with PersistenceNeighbourly Pharmacy Inc. has closed the previously announced plan of arrangement to be taken private by Persistence Capital Partners (PCP). "Today's announcement marks an important milestone for Neighbourly. We are excited for a bright future as a private company," said Skip Bourdo, chief executive officer of Neighbourly. "This going-private transaction provides us with increased flexibility to pursue our growth initiatives, invest in innovation and drive operational excellence. We are focused on continuing to grow our network of pharmacies and serve more communities across Canada." As a result of the transaction, the common shares are expected to be delisted from the Toronto Stock Exchange (TSX) at the close of trading on or about March 21, 2024. The company has submitted an application to cease to be a reporting issuer under applicable Canadian securities laws and to otherwise terminate the company's public reporting requirements.Reported Earnings • Feb 16Third quarter 2024 earnings released: CA$0.11 loss per share (vs CA$0.20 loss in 3Q 2023)Third quarter 2024 results: CA$0.11 loss per share (improved from CA$0.20 loss in 3Q 2023). Revenue: CA$284.0m (up 7.0% from 3Q 2023). Net loss: CA$4.83m (loss narrowed 46% from 3Q 2023). Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Consumer Retailing industry in Canada.Price Target Changed • Feb 01Price target decreased by 12% to CA$18.80Down from CA$21.29, the current price target is an average from 5 analysts. New target price is approximately in line with last closing price of CA$18.28. The company is forecast to post a net loss per share of CA$0.48 next year compared to a net loss per share of CA$0.37 last year.공고 • Jan 23Neighbourly Pharmacy Inc. Announces Executive ChangesNeighbourly Pharmacy Inc. announced the appointment of Maura Dyer as Senior Vice President, People and Culture. Ms. Dyer is a seasoned human resources executive with over 20 years of experience at well-respected Canadian healthcare, telecommunications, and financial services organizations. Her expertise in talent acquisition, employee development, and HR operations will be instrumental in enhancing Neighbourly's reputation as a workplace that attracts and retains top talent. Most recently, Ms. Dyer led several Human Resources functions at Extendicare Inc., a leading provider of care and services for seniors across Canada. At Neighbourly, Ms. Dyer will lead the People and Culture team and will play a critical role in advancing the Company's growth through the development and continuous improvement of a Talent and Culture strategy. Ms. Dyer succeeds Roy Wieschkowski, who has decided to retire from corporate life after five successful years leading the Human Resources and Payroll teams at Neighbourly, supporting the Company's rapid growth and culture evolution. Mr. Wieschkowski's retirement marks the end of an accomplished 38 year-long career, leading Human Resources functions across various industry sectors including pharmaceuticals, retail, chemical and manufacturing. Ms. Dyer joins the Neighbourly team effective February 12, 2024.더 많은 업데이트 보기Recent updates공고 • Aug 14Neighbourly Pharmacy Inc. Announces CFO ChangesNeighbourly Pharmacy Inc. announced the appointment of J.P. Arcand as Chief Financial Officer. Mr. Arcand is a seasoned retail finance executive with over 20 years of experience. Mr. Arcand joins Neighbourly from Helly Hansen, a leading designer and retailer of sports apparel owned by Canadian Tire Corporation, where he most recently served as CFO in Norway, overseeing its global operations across 40 countries and multiple channels. At Neighbourly, Mr. Arcand will oversee all aspects of Neighbourly's financial operations, including financial planning and analysis, accounting, and treasury functions. He will work closely with the rest of the executive team to support Neighbourly's long-term growth objectives. Mr. Arcand succeeds Billy Wong who is leaving Neighbourly for another opportunity. Mr. Arcand will be starting at Neighbourly effective August 19, 2024.공고 • Mar 23Neighbourly Pharmacy Inc. COM to Be Deleted from OTC EquityNeighbourly Pharmacy Inc. COM (Canada) will be deleted from OTC Equity effective March 22, 2024, due to Acquisition /Merger /Amalgamation.공고 • Mar 21+ 1 more updateNeighbourly Closes Go-Private Deal with PersistenceNeighbourly Pharmacy Inc. has closed the previously announced plan of arrangement to be taken private by Persistence Capital Partners (PCP). "Today's announcement marks an important milestone for Neighbourly. We are excited for a bright future as a private company," said Skip Bourdo, chief executive officer of Neighbourly. "This going-private transaction provides us with increased flexibility to pursue our growth initiatives, invest in innovation and drive operational excellence. We are focused on continuing to grow our network of pharmacies and serve more communities across Canada." As a result of the transaction, the common shares are expected to be delisted from the Toronto Stock Exchange (TSX) at the close of trading on or about March 21, 2024. The company has submitted an application to cease to be a reporting issuer under applicable Canadian securities laws and to otherwise terminate the company's public reporting requirements.Reported Earnings • Feb 16Third quarter 2024 earnings released: CA$0.11 loss per share (vs CA$0.20 loss in 3Q 2023)Third quarter 2024 results: CA$0.11 loss per share (improved from CA$0.20 loss in 3Q 2023). Revenue: CA$284.0m (up 7.0% from 3Q 2023). Net loss: CA$4.83m (loss narrowed 46% from 3Q 2023). Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Consumer Retailing industry in Canada.Price Target Changed • Feb 01Price target decreased by 12% to CA$18.80Down from CA$21.29, the current price target is an average from 5 analysts. New target price is approximately in line with last closing price of CA$18.28. The company is forecast to post a net loss per share of CA$0.48 next year compared to a net loss per share of CA$0.37 last year.공고 • Jan 23Neighbourly Pharmacy Inc. Announces Executive ChangesNeighbourly Pharmacy Inc. announced the appointment of Maura Dyer as Senior Vice President, People and Culture. Ms. Dyer is a seasoned human resources executive with over 20 years of experience at well-respected Canadian healthcare, telecommunications, and financial services organizations. Her expertise in talent acquisition, employee development, and HR operations will be instrumental in enhancing Neighbourly's reputation as a workplace that attracts and retains top talent. Most recently, Ms. Dyer led several Human Resources functions at Extendicare Inc., a leading provider of care and services for seniors across Canada. At Neighbourly, Ms. Dyer will lead the People and Culture team and will play a critical role in advancing the Company's growth through the development and continuous improvement of a Talent and Culture strategy. Ms. Dyer succeeds Roy Wieschkowski, who has decided to retire from corporate life after five successful years leading the Human Resources and Payroll teams at Neighbourly, supporting the Company's rapid growth and culture evolution. Mr. Wieschkowski's retirement marks the end of an accomplished 38 year-long career, leading Human Resources functions across various industry sectors including pharmaceuticals, retail, chemical and manufacturing. Ms. Dyer joins the Neighbourly team effective February 12, 2024.공고 • Jan 19Neighbourly Pharmacy Inc. to Report Q3, 2024 Results on Feb 13, 2024Neighbourly Pharmacy Inc. announced that they will report Q3, 2024 results at 7:00 AM, US Eastern Standard Time on Feb 13, 2024Upcoming Dividend • Nov 13Upcoming dividend of CA$0.045 per share at 1.0% yieldEligible shareholders must have bought the stock before 20 November 2023. Payment date: 19 December 2023. The company is not currently making a profit but it is cash flow positive. Trailing yield: 1.0%. Lower than top quartile of Canadian dividend payers (6.7%). Lower than average of industry peers (1.2%).Buying Opportunity • Oct 12Now 22% undervaluedOver the last 90 days, the stock is up 15%. The fair value is estimated to be CA$23.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 82% over the last year. Meanwhile, the company became loss making. Revenue is forecast to grow by 14% in a year. Earnings is forecast to grow by 46% in the next year.공고 • Oct 11Neighbourly Pharmacy Inc. to Report Q2, 2024 Results on Oct 24, 2023Neighbourly Pharmacy Inc. announced that they will report Q2, 2024 results Pre-Market on Oct 24, 2023공고 • Oct 05PCP GP, L.P. entered into a letter of intent to acquire remaining all unknown minority stake in Neighbourly Pharmacy Inc. (TSX:NBLY) for CAD 470 million.PCP GP, L.P. entered into a letter of intent to acquire remaining all unknown minority stake in Neighbourly Pharmacy Inc. (TSX:NBLY) for CAD 470 million on October 3, 2023. As per consideration, the Persistence Capital Partners will pay CAD 20.50 in cash for each share of Neighbourly Pharmacy. The PCP GP secured fully committed debt and equity financing. Devon Park Advisors provided capital raising services to PCP. PCP currently beneficially owns or has control or direction over, directly or indirectly, 22.4 million common shares. The transaction has been unanimously approved by the Neighbourly Pharmacy board of directors. The transaction is subject to a definitive agreement, regulatory, court and/or stock exchange approvals, receiving an updated Fairness Opinion from TD and approval from shareholders of Neighbourly Pharmacy. The transaction is expected to close in the last calendar quarter of 2023 or early in the first calendar quarter of 2024. TD Securities acted as financial and provided fairness opinion to Neighbourly Pharmacy. Scotiabank and RBC Capital Markets acted as financial advisors to PCP. Stikeman Elliott LLP acted as legal advisor to PCP on the transaction. McCarthy Tétrault LLP acted as independent legal advisor to the Transaction Committee.New Risk • Oct 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.Upcoming Dividend • Aug 21Upcoming dividend of CA$0.045 per share at 1.1% yieldEligible shareholders must have bought the stock before 28 August 2023. Payment date: 26 September 2023. The company is not currently making a profit but it is cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Canadian dividend payers (6.2%). Lower than average of industry peers (1.3%).분석 기사 • Aug 15Neighbourly Pharmacy (TSE:NBLY) Will Pay A Dividend Of CA$0.045Neighbourly Pharmacy Inc. ( TSE:NBLY ) has announced that it will pay a dividend of CA$0.045 per share on the 26th of...Breakeven Date Change • Aug 02Forecast breakeven date pushed back to 2025The 7 analysts covering Neighbourly Pharmacy previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of CA$7.10m in 2025. Average annual earnings growth of 98% is required to achieve expected profit on schedule.Reported Earnings • Aug 01First quarter 2024 earnings released: CA$0.27 loss per share (vs CA$0.029 loss in 1Q 2023)First quarter 2024 results: CA$0.27 loss per share (further deteriorated from CA$0.029 loss in 1Q 2023). Revenue: CA$196.8m (up 72% from 1Q 2023). Net loss: CA$12.1m (loss widened CA$11.1m from 1Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Consumer Retailing industry in Canada.공고 • Jul 14Neighbourly Pharmacy Inc. to Report Q1, 2024 Results on Aug 01, 2023Neighbourly Pharmacy Inc. announced that they will report Q1, 2024 results Pre-Market on Aug 01, 2023Upcoming Dividend • Jun 28Upcoming dividend of CA$0.045 per share at 1.1% yieldEligible shareholders must have bought the stock before 05 July 2023. Payment date: 03 August 2023. The company is not currently making a profit but it is cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Canadian dividend payers (6.4%). Lower than average of industry peers (1.4%).Recent Insider Transactions • Jun 18Independent Chairman of the Board recently bought CA$599k worth of stockOn the 15th of June, Stuart Elman bought around 34k shares on-market at roughly CA$17.78 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Stuart's only on-market trade for the last 12 months.공고 • Jun 09Neighbourly Pharmacy Inc. Announces Quarterly Dividend, Payable on August 3, 2023Neighbourly Pharmacy Inc. announced that a quarterly dividend will be paid on August 3, 2023, to the Company's common shareholders of record as of July 6, 2023. The amount of the dividend will be $0.045 for each common share. This dividend is an "eligible dividend" for Canadian income tax purposes.Reported Earnings • Jun 09Full year 2023 earnings released: CA$0.37 loss per share (vs CA$2.57 loss in FY 2022)Full year 2023 results: CA$0.37 loss per share (improved from CA$2.57 loss in FY 2022). Revenue: CA$749.1m (up 75% from FY 2022). Net loss: CA$15.5m (loss narrowed 79% from FY 2022). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Consumer Retailing industry in Canada.공고 • Jun 07Neighbourly Pharmacy Inc. (TSX:NBLY) entered into a binding agreement to acquire Seven Pharmacies in Western Canada.Neighbourly Pharmacy Inc. (TSX:NBLY) entered into a binding agreement to acquire Seven Pharmacies in Western Canada on June 6, 2023. The Acquisition will be funded from cash on hand and drawings on the Company’s credit facility. The deal is subject to pending customary regulatory approvals and the satisfaction of customary closing conditions. The deal is expected to close by the end of June 2023. The deal will generate total annualized Adjusted EBITDA of approximately CAD 4.4 million.공고 • May 26Neighbourly Pharmacy Inc. (TSX:NBLY) has entered into a binding agreement to acquire Three pharmacies in Ontario.Neighbourly Pharmacy Inc. (TSX:NBLY) has entered into a binding agreement to acquire Three pharmacies in Ontario on May 25, 2023. Acquisition will be funded from cash on hand and drawings on the Neighbourly Pharmacy Inc.’s credit facility. Upon completion of the Acquisition, Neighbourly’s network will comprise a total of 287 locations across Canada. Transaction has pending customary regulatory approvals and the satisfaction of customary closing conditions.. Transaction is expected to close by the end of June 2023.공고 • May 20Neighbourly Pharmacy Inc., Annual General Meeting, Aug 01, 2023Neighbourly Pharmacy Inc., Annual General Meeting, Aug 01, 2023.공고 • May 13Neighbourly Pharmacy Inc. to Report Q4, 2023 Results on Jun 08, 2023Neighbourly Pharmacy Inc. announced that they will report Q4, 2023 results Pre-Market on Jun 08, 2023분석 기사 • Mar 22Estimating The Fair Value Of Neighbourly Pharmacy Inc. (TSE:NBLY)Key Insights Using the 2 Stage Free Cash Flow to Equity, Neighbourly Pharmacy fair value estimate is CA$25.02 Current...Upcoming Dividend • Mar 06Upcoming dividend of CA$0.045 per share at 0.7% yieldEligible shareholders must have bought the stock before 13 March 2023. Payment date: 11 April 2023. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.7%. Lower than top quartile of Canadian dividend payers (5.9%). Lower than average of industry peers (1.3%).Recent Insider Transactions • Feb 27CEO & Director recently bought CA$272k worth of stockOn the 24th of February, Skip Bourdo bought around 11k shares on-market at roughly CA$24.57 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Skip's only on-market trade for the last 12 months.Breakeven Date Change • Feb 21Forecast breakeven date pushed back to 2024The 8 analysts covering Neighbourly Pharmacy previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 91% to 2023. The company is expected to make a profit of CA$12.5m in 2024. Average annual earnings growth of 125% is required to achieve expected profit on schedule.분석 기사 • Feb 17Results: Neighbourly Pharmacy Inc. Delivered A Surprise Loss And Now Analysts Have New ForecastsIt's been a good week for Neighbourly Pharmacy Inc. ( TSE:NBLY ) shareholders, because the company has just released...공고 • Feb 15Neighbourly Pharmacy Inc. Announces Quarterly Dividend, Payable on April 11, 2023Neighbourly Pharmacy Inc. announced that a quarterly dividend will be paid on April 11, 2023, to the Company's common shareholders of record as of March 14, 2023. The amount of the dividend will be $0.045 for each common share. This dividend is an "eligible dividend" for Canadian income tax purposes.Reported Earnings • Feb 14Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2023 results: CA$0.20 loss per share (further deteriorated from CA$0.026 loss in 3Q 2022). Revenue: CA$265.3m (up 91% from 3Q 2022). Net loss: CA$8.98m (loss widened CA$8.09m from 3Q 2022). Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Consumer Retailing industry in Canada.Major Estimate Revision • Feb 12Consensus EPS estimates fall by 42%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from CA$0.147 to CA$0.085 per share. Revenue forecast steady at CA$751.0m. Net income forecast to grow 103% next year vs 5.8% decline forecast for Consumer Retailing industry in Canada. Consensus price target of CA$29.44 unchanged from last update. Share price rose 11% to CA$23.23 over the past week.공고 • Jan 28Neighbourly Pharmacy Inc. to Report Q3, 2023 Results on Feb 14, 2023Neighbourly Pharmacy Inc. announced that they will report Q3, 2023 results Pre-Market on Feb 14, 2023공고 • Jan 25Neighbourly Pharmacy Inc. Announces CEO ChangesNeighbourly Pharmacy Inc. appointed Skip Bourdo as Chief Executive Officer. Chris Gardner has decided to step down as CEO and will continue to support the Company in a Strategic Advisor role. Skip Bourdo is an accomplished pharmacy and healthcare executive with 30 years of industry experience. Mr. Bourdo had a successful 27-year career at Walgreens, one of North America's pharmacy chains, starting as a cashier, then store manager, and growing in positions of ever-increasing responsibility, including integration and business transformation roles, and culminating as Group Vice President, Pharmacy and Retail Field Operations for Walgreens' Western operations, where he oversaw a network covering 4,700 retail, health system and specialty pharmacy locations, generating over $46 billion in revenue, and employing over 120,000 team members in 29 states, Puerto Rico and the U.S. Virgin Islands, serving nearly 4 million customers and patients every day. More recently, Mr. Bourdo was Chief Operating Officer of Athletico, a rapidly growing, leading provider of orthopedic rehabilitation services across the United States. During his tenure at Athletico, Mr. Bourdo was responsible for bringing operational excellence, structure, and scale capabilities to Athletico's clinic operations, which almost doubled their retail footprint to 950+ locations over the course of two years. The appointment of Skip Bourdo follows a rigorous search process, which considered high quality candidates from Canada and the USA. Chris Gardner continues to be committed to the success and growth of the Company and will remain with Neighbourly as a Strategic Advisor, supporting Mr. Bourdo and the Board of Directors over the next twelve months, including continuing to execute on the Company's robust acquisition pipeline. Mr. Gardner joined Neighbourly in 2017 and became CEO in February 2019 leading the Company's rapid growth -- driving a nearly five-fold increase from 61 locations to 284 locations coast to coast, as well as its public offering in 2021.공고 • Dec 20Neighbourly Pharmacy Inc. (TSX:NBLY) completed the acquisition of Cloverdale Pharmacy Ltd. and Steveston Health Centre Ltd. from CloudMD Software & Services Inc. (TSXV:DOC)Neighbourly Pharmacy Inc. (TSX:NBLY) entered into a binding agreement to acquire Cloverdale Pharmacy Ltd. and Steveston Health Centre Ltd. from CloudMD Software & Services Inc. (TSXV:DOC) for CAD 3.8 million on October 24, 2022. In a related transaction, Neighbourly Pharmacy Inc. (TSX:NBLY) enter into a binding agreement to acquire Six Community Pharmacies Located in New Brunswick and Nova Scotia on October 24, 2022. The total purchase price for the acquisitions is CAD 15.5 million. The Acquisitions will be funded from cash on hand and drawings on the Company’s credit facility. Neighbourly estimates that the eight acquired locations will generate total annualized Adjusted EBITDA of approximately CAD 2.7 million. Both Acquisitions are expected to close by the end of November 2022, pending customary regulatory approvals and the satisfaction of customary closing conditions. As of October 31, 2022, the transaction is expected to close in the fourth quarter of 2022. INFOR Financial Group acted as exclusive financial advisor and Cassels Brock & Blackwell LLP acted as legal advisor to CloudMD. Neighbourly Pharmacy Inc. (TSX:NBLY) completed the acquisition of Cloverdale Pharmacy Ltd. and Steveston Health Centre Ltd. from CloudMD Software & Services Inc. (TSXV:DOC) on December 19, 2022.분석 기사 • Dec 09Calculating The Fair Value Of Neighbourly Pharmacy Inc. (TSE:NBLY)Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Neighbourly Pharmacy...Board Change • Nov 16High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Independent Chairman of the Board Stuart Elman is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공고 • Oct 27Neighbourly Pharmacy Inc. Announces Quarterly Dividend, Payable on December 20, 2022Neighbourly Pharmacy Inc. announced that a quarterly dividend will be paid on December 20, 2022, to the Company's common shareholders of record as of November 22, 2022. The amount of the dividend will be $0.045 for each common share. This dividend is an "eligible dividend" for Canadian income tax purposes.Major Estimate Revision • Oct 26Consensus forecasts updatedThe consensus outlook for 2023 has been updated. 2023 EPS estimate increased from CA$0.19 to CA$0.27. Revenue forecast steady at CA$749.4m. Net income forecast to grow 53% next year vs 0.4% growth forecast for Consumer Retailing industry in Canada. Consensus price target broadly unchanged at CA$29.30. Share price rose 13% to CA$22.86 over the past week.공고 • Oct 26+ 1 more updateNeighbourly Pharmacy Inc. (TSX:NBLY) acquired Assets of a Retail Pharmacy Located in Manitoba.Neighbourly Pharmacy Inc. (TSX:NBLY) acquired Assets of a Retail Pharmacy Located in Manitoba on August 23, 2022. Neighbourly Pharmacy Inc. (TSX:NBLY) completed the acquisition of Assets of a Retail Pharmacy Located in Manitoba on August 23, 2022.공고 • Oct 25Neighbourly Pharmacy Inc. (TSX:NBLY) entered into a binding agreement to acquire Six Community Pharmacies Located in New Brunswick and Nova Scotia.Neighbourly Pharmacy Inc. (TSX:NBLY) entered into a binding agreement to acquire Six Community Pharmacies Located in New Brunswick and Nova Scotia on October 24, 2022. In a related tramsaction the Neighbourly Pharmacy Inc. also entered into a binding agreement to acquire two community pharmacies located in British Columbia. The total purchase price for the Acquisitions is $15.5 million. The Acquisitions will be funded from cash on hand and drawings on the Company’s credit facility. The transaction pending customary regulatory approvals and the satisfaction of customary closing conditions and expected to close by the end of November 2022.Major Estimate Revision • Oct 22Consensus forecasts updatedThe consensus outlook for 2023 has been updated. 2023 EPS estimate increased from CA$0.19 to CA$0.40. Revenue forecast steady at CA$751.0m. Net income forecast to grow 425% next year vs 0.4% growth forecast for Consumer Retailing industry in Canada. Consensus price target broadly unchanged at CA$29.30. Share price was steady at CA$21.01 over the past week.Buying Opportunity • Oct 18Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be CA$26.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 73% in a year. Earnings is forecast to grow by 425% in the next year.공고 • Aug 31Neighbourly Pharmacy Inc. Appoints Billy Wong as CFO to Succeed Terri SmythNeighbourly Pharmacy Inc. announced that Terri Smyth will be stepping away from her role as Chief Financial Officer for family reasons as she relocates to British Columbia with her family over the coming months. Ms. Smyth will continue in her capacity as CFO until October 25, 2022, when Neighbourly plans to release its second quarter 2023 financial results. Ms. Smyth continues to be committed to the success and growth of the business and will be remaining with the Company through March 2023, to ensure a seamless and orderly transition. Succeeding Terri Smyth is Billy Wong, a seasoned finance executive with more than 15 years in progressive roles of increased scope and responsibility in forecasting, planning, analysis, decision support and continuous improvement across various retail and consumer companies. Over the last four years, Mr. Wong was Chief Financial Officer at Camuto Group, Chief Financial Officer & Chief Operations Officer at Designer Brands Canada, both divisions of Designer Brands Inc. Prior to that, Mr. Wong was an Executive Vice President, CFO at Sears Canada. Mr. Wong will start at Neighbourly on September 19, 2022 and will work closely with Ms. Smyth over the coming months to ensure a smooth transition into the CFO role. Ms. Smyth will continue to support Mr. Wong through the balance of the fiscal year.Upcoming Dividend • Aug 22Upcoming dividend of CA$0.045 per shareEligible shareholders must have bought the stock before 29 August 2022. Payment date: 27 September 2022. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 0.9%. Lower than top quartile of Canadian dividend payers (5.4%). Lower than average of industry peers (1.2%).분석 기사 • Aug 10Neighbourly Pharmacy's (TSE:NBLY) Robust Earnings Are Supported By Other Strong FactorsEven though Neighbourly Pharmacy Inc.'s ( TSE:NBLY ) recent earnings release was robust, the market didn't seem to...Reported Earnings • Aug 03First quarter 2023 earnings: EPS misses analyst expectationsFirst quarter 2023 results: CA$0.029 loss per share (up from CA$7.50 loss in 1Q 2022). Revenue: CA$114.4m (up 34% from 1Q 2022). Net loss: CA$999.0k (loss narrowed 99% from 1Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 74%, compared to a 7.7% growth forecast for the industry in Canada.공고 • Aug 03Neighbourly Pharmacy Inc. Declares Dividend on Common Share for the First Quarter Ended June 18, 2022, Payable on September 27, 2022Neighbourly Pharmacy Inc. announced its dividend of $0.045 for each common share for the first quarter ended June 18, 2022. The dividend will be paid on September 27, 2022, to the Company's common shareholders of record as of August 30, 2022.Upcoming Dividend • Jul 13Upcoming dividend of CA$0.045 per shareEligible shareholders must have bought the stock before 20 July 2022. Payment date: 18 August 2022. The company is not currently making a profit and its cash payout ratio is 76%. Trailing yield: 0.8%. Lower than top quartile of Canadian dividend payers (5.5%). Lower than average of industry peers (1.2%).공고 • Jun 29Neighbourly Pharmacy Inc. (TSX:NBLY) completed the acquisition of Rubicon Pharmacies Canada Inc.Neighbourly Pharmacy Inc. (TSX:NBLY) entered into a definitive agreement to acquire Rubicon Pharmacies Canada Inc. for approximately CAD 440 million on March 10, 2022. The acquisition is for a Cash purchase price of approximately CAD 440 million. The Acquisition will be partially financed through a CAD 250 million equity issuance of subscription receipts, of which approximately 48% will be purchased on a private placement basis by an affiliate of Persistence Capital Partners, Neighbourly’s largest shareholder, and the balance will be distributed by way of public offering. The balance of the purchase price will be financed through draw downs on the Company’s Restated Credit Facilities and cash on hand. In connection with the Acquisition, affiliates of Scotiabank and RBC provided a commitment letter providing for commitments to replace or amend and restate the Company’s existing credit agreement with the following credit facilities: (a) CAD 200 million revolving credit facility maturing May 25, 2026, (b) an upsized CAD 200 million senior term loan credit facility maturing May 25, 2026, and (c) a new CAD 250 million bridge credit facility. Rubicon generated approximately CAD 303 million of revenue and approximately CAD 39 million of EBITDA during the twelve-month period ended September 30, 2021. The Acquisition has been unanimously approved by the directors of Neighbourly, and remain subject to customary closing conditions, including regulatory approvals. In addition, the conditions to the completion of the Acquisition in the Purchase Agreement include that any ROFR shall have either been extinguished or waived by the applicable ROFR party, or that the transaction pursuant to which the applicable ROFR parties acquired any ROFR Pharmacies shall have been consummated. As of June 7, 2022 Neighbourly Pharmacy Inc. received a "no-action letter" from the Competition Bureau to proceed with its previously announced acquisition of Rubicon Pharmacies. Neighbourly expects the completion of the acquisition to occur on June 27, 2022. The Acquisition is expected to occur during the first quarter of Fiscal 2023 (the second quarter of the calendar year 2022). As of June 23, 2022 the Rubicon Acquisition is expected to close by the end of June 2022. Royal Bank of Canada (TSX:RY) acted as financial advisor to Neighbourly Pharmacy Inc. The Bank of Nova Scotia (TSX:BNS) acted as financial advisor to Neighbourly Pharmacy Inc. Benjamin Bloom, Frank DeLuca, Melodie D. Eng and Marc Senderowitz of Minden Gross LLP acted as legal advisor to Neighbourly Pharmacy Inc. Stikeman Elliott LLP acted as legal advisor to Neighbourly Pharmacy Inc. Guy Berman, Danielle Traub, Justin Crawford, Nick Germanakos, Erica Bird and Jessica Reid (corporate/M&A), Teresa Reguly (food and drug regulatory), Omar Wakil and Ian Li (competition), Tom Stevenson (employment), Andy Gibbons (real estate), Jerald Wortsman and Benjamin Mann (tax) of Torys LLP acted as legal advisors to Rubicon Pharmacies in the transaction. RBC Capital Markets acted as financial advisor to Neighbourly pharmacy. Neighbourly Pharmacy Inc. (TSX:NBLY) completed the acquisition of Rubicon Pharmacies Canada Inc. on June 27, 2022.Reported Earnings • Jun 25Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: CA$2.57 loss per share (up from CA$199 loss in FY 2021). Revenue: CA$427.5m (up 40% from FY 2021). Net loss: CA$73.4m (loss narrowed 20% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 11%. Over the next year, revenue is forecast to grow 78%, compared to a 6.5% growth forecast for the retail industry in Canada.Price Target Changed • Jun 24Price target decreased to CA$33.44Down from CA$37.00, the current price target is an average from 9 analysts. New target price is 36% above last closing price of CA$24.54. Stock is down 12% over the past year.공고 • Jun 24Neighbourly Pharmacy Inc. Announces Quarterly Dividend, Payable on August 18, 2022Neighbourly Pharmacy Inc. announced that a quarterly dividend will be paid on August 18, 2022, to the Company's common shareholders of record as of July 21, 2022. The amount of the dividend will be $0.045 for each common share.공고 • Jun 06+ 1 more updateNeighbourly Pharmacy Inc. to Report Q1, 2023 Results on Aug 02, 2022Neighbourly Pharmacy Inc. announced that they will report Q1, 2023 results on Aug 02, 2022공고 • May 27Neighbourly Pharmacy Inc., Annual General Meeting, Aug 02, 2022Neighbourly Pharmacy Inc., Annual General Meeting, Aug 02, 2022.공고 • May 18Neighbourly Pharmacy Inc. to Report Q4, 2022 Results on Jun 23, 2022Neighbourly Pharmacy Inc. announced that they will report Q4, 2022 results Pre-Market on Jun 23, 2022Board Change • Apr 27High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Independent Chairman of the Board Stuart Elman is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공고 • Apr 15Neighbourly Pharmacy Inc. announced that it has received CAD 138.163875 million in funding from PCP GP, L.P.On April 14, 2022, Neighbourly Pharmacy Inc. closed the transaction. The company amended the terms of the transaction, and issued 622,500 subscription receipts for gross proceeds of CAD 18,021,375 in its second tranche closing, bringing the total gross proceeds raised in the transaction to CAD 138,163,875.분석 기사 • Mar 21News Flash: Analysts Just Made A Substantial Upgrade To Their Neighbourly Pharmacy Inc. (TSE:NBLY) ForecastsNeighbourly Pharmacy Inc. ( TSE:NBLY ) shareholders will have a reason to smile today, with the analysts making...Upcoming Dividend • Mar 07Upcoming dividend of CA$0.045 per shareEligible shareholders must have bought the stock before 14 March 2022. Payment date: 12 April 2022. The company is not currently making a profit and its cash payout ratio is 79%. Trailing yield: 0.6%. Lower than top quartile of Canadian dividend payers (4.8%). Lower than average of industry peers (1.3%).분석 기사 • Feb 27Is There An Opportunity With Neighbourly Pharmacy Inc.'s (TSE:NBLY) 48% Undervaluation?In this article we are going to estimate the intrinsic value of Neighbourly Pharmacy Inc. ( TSE:NBLY ) by taking the...Reported Earnings • Feb 16Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: CA$0.03 loss per share (up from CA$245 loss in 3Q 2021). Revenue: CA$139.2m (up 27% from 3Q 2021). Net loss: CA$889.0k (loss narrowed 99% from 3Q 2021). Revenue missed analyst estimates by 2.7%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to grow 38%, compared to a 5.5% growth forecast for the industry in Canada.공고 • Feb 16+ 2 more updatesNeighbourly Pharmacy Inc. (TSX:NBLY) entered into an agreement to acquire one additional pharmacy in Canada.Neighbourly Pharmacy Inc. (TSX:NBLY) entered into an agreement to acquire one additional pharmacy in Canada on February 15, 2022.Major Estimate Revision • Feb 13Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -CA$1.41 to -CA$2.12 per share. Revenue forecast of CA$431.9m unchanged since last update. Consumer Retailing industry in Canada expected to see average net income growth of 13% next year. Consensus price target of CA$34.88 unchanged from last update. Share price rose 3.9% to CA$31.84 over the past week.Upcoming Dividend • Nov 15Upcoming dividend of CA$0.045 per shareEligible shareholders must have bought the stock before 22 November 2021. Payment date: 21 December 2021. Trailing yield: 0.5%. Lower than top quartile of Canadian dividend payers (4.5%). Lower than average of industry peers (1.2%).Reported Earnings • Oct 27Second quarter 2022 earnings released: CA$0.11 loss per share (vs CA$24.48 loss in 2Q 2021)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2022 results: Revenue: CA$90.7m (down 17% from 2Q 2021). Net loss: CA$3.65m (loss narrowed 97% from 2Q 2021).Upcoming Dividend • Sep 06Upcoming dividend of CA$0.045 per shareEligible shareholders must have bought the stock before 13 September 2021. Payment date: 12 October 2021. Trailing yield: 0.5%. Lower than top quartile of Canadian dividend payers (4.6%). Lower than average of industry peers (1.3%).Breakeven Date Change • Aug 05Forecast breakeven pushed back to 2023The 6 analysts covering Neighbourly Pharmacy previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 47% to 2022. The company is expected to make a profit of CA$33.9m in 2023. Average annual earnings growth of 102% is required to achieve expected profit on schedule.Reported Earnings • Jun 28Full year 2021 earnings released: CA$19.88 loss per share (vs CA$5.08 loss in FY 2020)The company reported a mediocre full year result with increased losses and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: CA$306.5m (up 64% from FY 2020). Net loss: CA$91.3m (loss widened 291% from FY 2020).공고 • Jun 25+ 2 more updatesNeighbourly Pharmacy Inc. (TSX:NBLY) acquired One Pharmacy in Canada.Neighbourly Pharmacy Inc. (TSX:NBLY) acquired One Pharmacy in Canada on June 22, 2021. Neighbourly Pharmacy Inc. (TSX:NBLY) completed the acquisition of One Pharmacy in Canada on June 22, 2021.공고 • May 26Neighbourly Pharmacy Inc. has completed an IPO in the amount of CAD 175.015 million.Neighbourly Pharmacy Inc. has completed an IPO in the amount of CAD 175.015 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 10,295,000 Price\Range: CAD 17 Discount Per Security: CAD 1.02 Transaction Features: Regulation S; Rule 144A; Sponsor Backed Offering주주 수익률NBLYCA Consumer RetailingCA 시장7D0.05%2.3%-0.9%1Y-13.4%15.9%28.5%전체 주주 수익률 보기수익률 대 산업: NBLY은 지난 1년 동안 15.9%의 수익을 기록한 Canadian Consumer Retailing 산업보다 저조한 성과를 냈습니다.수익률 대 시장: NBLY은 지난 1년 동안 28.5%를 기록한 Canadian 시장보다 저조한 성과를 냈습니다.주가 변동성Is NBLY's price volatile compared to industry and market?NBLY volatilityNBLY Average Weekly Movement5.0%Consumer Retailing Industry Average Movement4.0%Market Average Movement9.3%10% most volatile stocks in CA Market16.3%10% least volatile stocks in CA Market3.6%안정적인 주가: NBLY는 지난 3개월 동안 Canadian 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: NBLY의 주간 변동성(5%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트20153,648Skip Bourdoneighbourlypharmacy.ca더 보기Neighbourly Pharmacy Inc. 기초 지표 요약Neighbourly Pharmacy의 순이익과 매출은 시가총액과 어떻게 비교됩니까?NBLY 기초 통계시가총액CA$840.40m순이익 (TTM)-CA$32.70m매출 (TTM)CA$874.61m1.0x주가매출비율(P/S)-25.6x주가수익비율(P/E)NBLY는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표NBLY 손익계산서 (TTM)매출CA$874.61m매출원가CA$527.56m총이익CA$347.05m기타 비용CA$379.76m순이익-CA$32.70m최근 보고된 실적Dec 30, 2023다음 실적 발표일해당 없음주당순이익(EPS)-0.72총이익률39.68%순이익률-3.74%부채/자본 비율44.5%NBLY의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/03/20 22:23종가2024/03/20 00:00수익2023/12/30연간 수익2023/03/25데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Neighbourly Pharmacy Inc.는 7명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kyle McPheeATB Cormark Historical (Cormark Securities)Clarence PowellBMO Capital Markets Equity ResearchChristopher LiDesjardins Securities Inc.4명의 분석가 더 보기
공고 • Aug 14Neighbourly Pharmacy Inc. Announces CFO ChangesNeighbourly Pharmacy Inc. announced the appointment of J.P. Arcand as Chief Financial Officer. Mr. Arcand is a seasoned retail finance executive with over 20 years of experience. Mr. Arcand joins Neighbourly from Helly Hansen, a leading designer and retailer of sports apparel owned by Canadian Tire Corporation, where he most recently served as CFO in Norway, overseeing its global operations across 40 countries and multiple channels. At Neighbourly, Mr. Arcand will oversee all aspects of Neighbourly's financial operations, including financial planning and analysis, accounting, and treasury functions. He will work closely with the rest of the executive team to support Neighbourly's long-term growth objectives. Mr. Arcand succeeds Billy Wong who is leaving Neighbourly for another opportunity. Mr. Arcand will be starting at Neighbourly effective August 19, 2024.
공고 • Mar 23Neighbourly Pharmacy Inc. COM to Be Deleted from OTC EquityNeighbourly Pharmacy Inc. COM (Canada) will be deleted from OTC Equity effective March 22, 2024, due to Acquisition /Merger /Amalgamation.
공고 • Mar 21+ 1 more updateNeighbourly Closes Go-Private Deal with PersistenceNeighbourly Pharmacy Inc. has closed the previously announced plan of arrangement to be taken private by Persistence Capital Partners (PCP). "Today's announcement marks an important milestone for Neighbourly. We are excited for a bright future as a private company," said Skip Bourdo, chief executive officer of Neighbourly. "This going-private transaction provides us with increased flexibility to pursue our growth initiatives, invest in innovation and drive operational excellence. We are focused on continuing to grow our network of pharmacies and serve more communities across Canada." As a result of the transaction, the common shares are expected to be delisted from the Toronto Stock Exchange (TSX) at the close of trading on or about March 21, 2024. The company has submitted an application to cease to be a reporting issuer under applicable Canadian securities laws and to otherwise terminate the company's public reporting requirements.
Reported Earnings • Feb 16Third quarter 2024 earnings released: CA$0.11 loss per share (vs CA$0.20 loss in 3Q 2023)Third quarter 2024 results: CA$0.11 loss per share (improved from CA$0.20 loss in 3Q 2023). Revenue: CA$284.0m (up 7.0% from 3Q 2023). Net loss: CA$4.83m (loss narrowed 46% from 3Q 2023). Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Consumer Retailing industry in Canada.
Price Target Changed • Feb 01Price target decreased by 12% to CA$18.80Down from CA$21.29, the current price target is an average from 5 analysts. New target price is approximately in line with last closing price of CA$18.28. The company is forecast to post a net loss per share of CA$0.48 next year compared to a net loss per share of CA$0.37 last year.
공고 • Jan 23Neighbourly Pharmacy Inc. Announces Executive ChangesNeighbourly Pharmacy Inc. announced the appointment of Maura Dyer as Senior Vice President, People and Culture. Ms. Dyer is a seasoned human resources executive with over 20 years of experience at well-respected Canadian healthcare, telecommunications, and financial services organizations. Her expertise in talent acquisition, employee development, and HR operations will be instrumental in enhancing Neighbourly's reputation as a workplace that attracts and retains top talent. Most recently, Ms. Dyer led several Human Resources functions at Extendicare Inc., a leading provider of care and services for seniors across Canada. At Neighbourly, Ms. Dyer will lead the People and Culture team and will play a critical role in advancing the Company's growth through the development and continuous improvement of a Talent and Culture strategy. Ms. Dyer succeeds Roy Wieschkowski, who has decided to retire from corporate life after five successful years leading the Human Resources and Payroll teams at Neighbourly, supporting the Company's rapid growth and culture evolution. Mr. Wieschkowski's retirement marks the end of an accomplished 38 year-long career, leading Human Resources functions across various industry sectors including pharmaceuticals, retail, chemical and manufacturing. Ms. Dyer joins the Neighbourly team effective February 12, 2024.
공고 • Aug 14Neighbourly Pharmacy Inc. Announces CFO ChangesNeighbourly Pharmacy Inc. announced the appointment of J.P. Arcand as Chief Financial Officer. Mr. Arcand is a seasoned retail finance executive with over 20 years of experience. Mr. Arcand joins Neighbourly from Helly Hansen, a leading designer and retailer of sports apparel owned by Canadian Tire Corporation, where he most recently served as CFO in Norway, overseeing its global operations across 40 countries and multiple channels. At Neighbourly, Mr. Arcand will oversee all aspects of Neighbourly's financial operations, including financial planning and analysis, accounting, and treasury functions. He will work closely with the rest of the executive team to support Neighbourly's long-term growth objectives. Mr. Arcand succeeds Billy Wong who is leaving Neighbourly for another opportunity. Mr. Arcand will be starting at Neighbourly effective August 19, 2024.
공고 • Mar 23Neighbourly Pharmacy Inc. COM to Be Deleted from OTC EquityNeighbourly Pharmacy Inc. COM (Canada) will be deleted from OTC Equity effective March 22, 2024, due to Acquisition /Merger /Amalgamation.
공고 • Mar 21+ 1 more updateNeighbourly Closes Go-Private Deal with PersistenceNeighbourly Pharmacy Inc. has closed the previously announced plan of arrangement to be taken private by Persistence Capital Partners (PCP). "Today's announcement marks an important milestone for Neighbourly. We are excited for a bright future as a private company," said Skip Bourdo, chief executive officer of Neighbourly. "This going-private transaction provides us with increased flexibility to pursue our growth initiatives, invest in innovation and drive operational excellence. We are focused on continuing to grow our network of pharmacies and serve more communities across Canada." As a result of the transaction, the common shares are expected to be delisted from the Toronto Stock Exchange (TSX) at the close of trading on or about March 21, 2024. The company has submitted an application to cease to be a reporting issuer under applicable Canadian securities laws and to otherwise terminate the company's public reporting requirements.
Reported Earnings • Feb 16Third quarter 2024 earnings released: CA$0.11 loss per share (vs CA$0.20 loss in 3Q 2023)Third quarter 2024 results: CA$0.11 loss per share (improved from CA$0.20 loss in 3Q 2023). Revenue: CA$284.0m (up 7.0% from 3Q 2023). Net loss: CA$4.83m (loss narrowed 46% from 3Q 2023). Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Consumer Retailing industry in Canada.
Price Target Changed • Feb 01Price target decreased by 12% to CA$18.80Down from CA$21.29, the current price target is an average from 5 analysts. New target price is approximately in line with last closing price of CA$18.28. The company is forecast to post a net loss per share of CA$0.48 next year compared to a net loss per share of CA$0.37 last year.
공고 • Jan 23Neighbourly Pharmacy Inc. Announces Executive ChangesNeighbourly Pharmacy Inc. announced the appointment of Maura Dyer as Senior Vice President, People and Culture. Ms. Dyer is a seasoned human resources executive with over 20 years of experience at well-respected Canadian healthcare, telecommunications, and financial services organizations. Her expertise in talent acquisition, employee development, and HR operations will be instrumental in enhancing Neighbourly's reputation as a workplace that attracts and retains top talent. Most recently, Ms. Dyer led several Human Resources functions at Extendicare Inc., a leading provider of care and services for seniors across Canada. At Neighbourly, Ms. Dyer will lead the People and Culture team and will play a critical role in advancing the Company's growth through the development and continuous improvement of a Talent and Culture strategy. Ms. Dyer succeeds Roy Wieschkowski, who has decided to retire from corporate life after five successful years leading the Human Resources and Payroll teams at Neighbourly, supporting the Company's rapid growth and culture evolution. Mr. Wieschkowski's retirement marks the end of an accomplished 38 year-long career, leading Human Resources functions across various industry sectors including pharmaceuticals, retail, chemical and manufacturing. Ms. Dyer joins the Neighbourly team effective February 12, 2024.
공고 • Jan 19Neighbourly Pharmacy Inc. to Report Q3, 2024 Results on Feb 13, 2024Neighbourly Pharmacy Inc. announced that they will report Q3, 2024 results at 7:00 AM, US Eastern Standard Time on Feb 13, 2024
Upcoming Dividend • Nov 13Upcoming dividend of CA$0.045 per share at 1.0% yieldEligible shareholders must have bought the stock before 20 November 2023. Payment date: 19 December 2023. The company is not currently making a profit but it is cash flow positive. Trailing yield: 1.0%. Lower than top quartile of Canadian dividend payers (6.7%). Lower than average of industry peers (1.2%).
Buying Opportunity • Oct 12Now 22% undervaluedOver the last 90 days, the stock is up 15%. The fair value is estimated to be CA$23.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 82% over the last year. Meanwhile, the company became loss making. Revenue is forecast to grow by 14% in a year. Earnings is forecast to grow by 46% in the next year.
공고 • Oct 11Neighbourly Pharmacy Inc. to Report Q2, 2024 Results on Oct 24, 2023Neighbourly Pharmacy Inc. announced that they will report Q2, 2024 results Pre-Market on Oct 24, 2023
공고 • Oct 05PCP GP, L.P. entered into a letter of intent to acquire remaining all unknown minority stake in Neighbourly Pharmacy Inc. (TSX:NBLY) for CAD 470 million.PCP GP, L.P. entered into a letter of intent to acquire remaining all unknown minority stake in Neighbourly Pharmacy Inc. (TSX:NBLY) for CAD 470 million on October 3, 2023. As per consideration, the Persistence Capital Partners will pay CAD 20.50 in cash for each share of Neighbourly Pharmacy. The PCP GP secured fully committed debt and equity financing. Devon Park Advisors provided capital raising services to PCP. PCP currently beneficially owns or has control or direction over, directly or indirectly, 22.4 million common shares. The transaction has been unanimously approved by the Neighbourly Pharmacy board of directors. The transaction is subject to a definitive agreement, regulatory, court and/or stock exchange approvals, receiving an updated Fairness Opinion from TD and approval from shareholders of Neighbourly Pharmacy. The transaction is expected to close in the last calendar quarter of 2023 or early in the first calendar quarter of 2024. TD Securities acted as financial and provided fairness opinion to Neighbourly Pharmacy. Scotiabank and RBC Capital Markets acted as financial advisors to PCP. Stikeman Elliott LLP acted as legal advisor to PCP on the transaction. McCarthy Tétrault LLP acted as independent legal advisor to the Transaction Committee.
New Risk • Oct 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
Upcoming Dividend • Aug 21Upcoming dividend of CA$0.045 per share at 1.1% yieldEligible shareholders must have bought the stock before 28 August 2023. Payment date: 26 September 2023. The company is not currently making a profit but it is cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Canadian dividend payers (6.2%). Lower than average of industry peers (1.3%).
분석 기사 • Aug 15Neighbourly Pharmacy (TSE:NBLY) Will Pay A Dividend Of CA$0.045Neighbourly Pharmacy Inc. ( TSE:NBLY ) has announced that it will pay a dividend of CA$0.045 per share on the 26th of...
Breakeven Date Change • Aug 02Forecast breakeven date pushed back to 2025The 7 analysts covering Neighbourly Pharmacy previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of CA$7.10m in 2025. Average annual earnings growth of 98% is required to achieve expected profit on schedule.
Reported Earnings • Aug 01First quarter 2024 earnings released: CA$0.27 loss per share (vs CA$0.029 loss in 1Q 2023)First quarter 2024 results: CA$0.27 loss per share (further deteriorated from CA$0.029 loss in 1Q 2023). Revenue: CA$196.8m (up 72% from 1Q 2023). Net loss: CA$12.1m (loss widened CA$11.1m from 1Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Consumer Retailing industry in Canada.
공고 • Jul 14Neighbourly Pharmacy Inc. to Report Q1, 2024 Results on Aug 01, 2023Neighbourly Pharmacy Inc. announced that they will report Q1, 2024 results Pre-Market on Aug 01, 2023
Upcoming Dividend • Jun 28Upcoming dividend of CA$0.045 per share at 1.1% yieldEligible shareholders must have bought the stock before 05 July 2023. Payment date: 03 August 2023. The company is not currently making a profit but it is cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Canadian dividend payers (6.4%). Lower than average of industry peers (1.4%).
Recent Insider Transactions • Jun 18Independent Chairman of the Board recently bought CA$599k worth of stockOn the 15th of June, Stuart Elman bought around 34k shares on-market at roughly CA$17.78 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Stuart's only on-market trade for the last 12 months.
공고 • Jun 09Neighbourly Pharmacy Inc. Announces Quarterly Dividend, Payable on August 3, 2023Neighbourly Pharmacy Inc. announced that a quarterly dividend will be paid on August 3, 2023, to the Company's common shareholders of record as of July 6, 2023. The amount of the dividend will be $0.045 for each common share. This dividend is an "eligible dividend" for Canadian income tax purposes.
Reported Earnings • Jun 09Full year 2023 earnings released: CA$0.37 loss per share (vs CA$2.57 loss in FY 2022)Full year 2023 results: CA$0.37 loss per share (improved from CA$2.57 loss in FY 2022). Revenue: CA$749.1m (up 75% from FY 2022). Net loss: CA$15.5m (loss narrowed 79% from FY 2022). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Consumer Retailing industry in Canada.
공고 • Jun 07Neighbourly Pharmacy Inc. (TSX:NBLY) entered into a binding agreement to acquire Seven Pharmacies in Western Canada.Neighbourly Pharmacy Inc. (TSX:NBLY) entered into a binding agreement to acquire Seven Pharmacies in Western Canada on June 6, 2023. The Acquisition will be funded from cash on hand and drawings on the Company’s credit facility. The deal is subject to pending customary regulatory approvals and the satisfaction of customary closing conditions. The deal is expected to close by the end of June 2023. The deal will generate total annualized Adjusted EBITDA of approximately CAD 4.4 million.
공고 • May 26Neighbourly Pharmacy Inc. (TSX:NBLY) has entered into a binding agreement to acquire Three pharmacies in Ontario.Neighbourly Pharmacy Inc. (TSX:NBLY) has entered into a binding agreement to acquire Three pharmacies in Ontario on May 25, 2023. Acquisition will be funded from cash on hand and drawings on the Neighbourly Pharmacy Inc.’s credit facility. Upon completion of the Acquisition, Neighbourly’s network will comprise a total of 287 locations across Canada. Transaction has pending customary regulatory approvals and the satisfaction of customary closing conditions.. Transaction is expected to close by the end of June 2023.
공고 • May 20Neighbourly Pharmacy Inc., Annual General Meeting, Aug 01, 2023Neighbourly Pharmacy Inc., Annual General Meeting, Aug 01, 2023.
공고 • May 13Neighbourly Pharmacy Inc. to Report Q4, 2023 Results on Jun 08, 2023Neighbourly Pharmacy Inc. announced that they will report Q4, 2023 results Pre-Market on Jun 08, 2023
분석 기사 • Mar 22Estimating The Fair Value Of Neighbourly Pharmacy Inc. (TSE:NBLY)Key Insights Using the 2 Stage Free Cash Flow to Equity, Neighbourly Pharmacy fair value estimate is CA$25.02 Current...
Upcoming Dividend • Mar 06Upcoming dividend of CA$0.045 per share at 0.7% yieldEligible shareholders must have bought the stock before 13 March 2023. Payment date: 11 April 2023. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.7%. Lower than top quartile of Canadian dividend payers (5.9%). Lower than average of industry peers (1.3%).
Recent Insider Transactions • Feb 27CEO & Director recently bought CA$272k worth of stockOn the 24th of February, Skip Bourdo bought around 11k shares on-market at roughly CA$24.57 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Skip's only on-market trade for the last 12 months.
Breakeven Date Change • Feb 21Forecast breakeven date pushed back to 2024The 8 analysts covering Neighbourly Pharmacy previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 91% to 2023. The company is expected to make a profit of CA$12.5m in 2024. Average annual earnings growth of 125% is required to achieve expected profit on schedule.
분석 기사 • Feb 17Results: Neighbourly Pharmacy Inc. Delivered A Surprise Loss And Now Analysts Have New ForecastsIt's been a good week for Neighbourly Pharmacy Inc. ( TSE:NBLY ) shareholders, because the company has just released...
공고 • Feb 15Neighbourly Pharmacy Inc. Announces Quarterly Dividend, Payable on April 11, 2023Neighbourly Pharmacy Inc. announced that a quarterly dividend will be paid on April 11, 2023, to the Company's common shareholders of record as of March 14, 2023. The amount of the dividend will be $0.045 for each common share. This dividend is an "eligible dividend" for Canadian income tax purposes.
Reported Earnings • Feb 14Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2023 results: CA$0.20 loss per share (further deteriorated from CA$0.026 loss in 3Q 2022). Revenue: CA$265.3m (up 91% from 3Q 2022). Net loss: CA$8.98m (loss widened CA$8.09m from 3Q 2022). Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Consumer Retailing industry in Canada.
Major Estimate Revision • Feb 12Consensus EPS estimates fall by 42%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from CA$0.147 to CA$0.085 per share. Revenue forecast steady at CA$751.0m. Net income forecast to grow 103% next year vs 5.8% decline forecast for Consumer Retailing industry in Canada. Consensus price target of CA$29.44 unchanged from last update. Share price rose 11% to CA$23.23 over the past week.
공고 • Jan 28Neighbourly Pharmacy Inc. to Report Q3, 2023 Results on Feb 14, 2023Neighbourly Pharmacy Inc. announced that they will report Q3, 2023 results Pre-Market on Feb 14, 2023
공고 • Jan 25Neighbourly Pharmacy Inc. Announces CEO ChangesNeighbourly Pharmacy Inc. appointed Skip Bourdo as Chief Executive Officer. Chris Gardner has decided to step down as CEO and will continue to support the Company in a Strategic Advisor role. Skip Bourdo is an accomplished pharmacy and healthcare executive with 30 years of industry experience. Mr. Bourdo had a successful 27-year career at Walgreens, one of North America's pharmacy chains, starting as a cashier, then store manager, and growing in positions of ever-increasing responsibility, including integration and business transformation roles, and culminating as Group Vice President, Pharmacy and Retail Field Operations for Walgreens' Western operations, where he oversaw a network covering 4,700 retail, health system and specialty pharmacy locations, generating over $46 billion in revenue, and employing over 120,000 team members in 29 states, Puerto Rico and the U.S. Virgin Islands, serving nearly 4 million customers and patients every day. More recently, Mr. Bourdo was Chief Operating Officer of Athletico, a rapidly growing, leading provider of orthopedic rehabilitation services across the United States. During his tenure at Athletico, Mr. Bourdo was responsible for bringing operational excellence, structure, and scale capabilities to Athletico's clinic operations, which almost doubled their retail footprint to 950+ locations over the course of two years. The appointment of Skip Bourdo follows a rigorous search process, which considered high quality candidates from Canada and the USA. Chris Gardner continues to be committed to the success and growth of the Company and will remain with Neighbourly as a Strategic Advisor, supporting Mr. Bourdo and the Board of Directors over the next twelve months, including continuing to execute on the Company's robust acquisition pipeline. Mr. Gardner joined Neighbourly in 2017 and became CEO in February 2019 leading the Company's rapid growth -- driving a nearly five-fold increase from 61 locations to 284 locations coast to coast, as well as its public offering in 2021.
공고 • Dec 20Neighbourly Pharmacy Inc. (TSX:NBLY) completed the acquisition of Cloverdale Pharmacy Ltd. and Steveston Health Centre Ltd. from CloudMD Software & Services Inc. (TSXV:DOC)Neighbourly Pharmacy Inc. (TSX:NBLY) entered into a binding agreement to acquire Cloverdale Pharmacy Ltd. and Steveston Health Centre Ltd. from CloudMD Software & Services Inc. (TSXV:DOC) for CAD 3.8 million on October 24, 2022. In a related transaction, Neighbourly Pharmacy Inc. (TSX:NBLY) enter into a binding agreement to acquire Six Community Pharmacies Located in New Brunswick and Nova Scotia on October 24, 2022. The total purchase price for the acquisitions is CAD 15.5 million. The Acquisitions will be funded from cash on hand and drawings on the Company’s credit facility. Neighbourly estimates that the eight acquired locations will generate total annualized Adjusted EBITDA of approximately CAD 2.7 million. Both Acquisitions are expected to close by the end of November 2022, pending customary regulatory approvals and the satisfaction of customary closing conditions. As of October 31, 2022, the transaction is expected to close in the fourth quarter of 2022. INFOR Financial Group acted as exclusive financial advisor and Cassels Brock & Blackwell LLP acted as legal advisor to CloudMD. Neighbourly Pharmacy Inc. (TSX:NBLY) completed the acquisition of Cloverdale Pharmacy Ltd. and Steveston Health Centre Ltd. from CloudMD Software & Services Inc. (TSXV:DOC) on December 19, 2022.
분석 기사 • Dec 09Calculating The Fair Value Of Neighbourly Pharmacy Inc. (TSE:NBLY)Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Neighbourly Pharmacy...
Board Change • Nov 16High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Independent Chairman of the Board Stuart Elman is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공고 • Oct 27Neighbourly Pharmacy Inc. Announces Quarterly Dividend, Payable on December 20, 2022Neighbourly Pharmacy Inc. announced that a quarterly dividend will be paid on December 20, 2022, to the Company's common shareholders of record as of November 22, 2022. The amount of the dividend will be $0.045 for each common share. This dividend is an "eligible dividend" for Canadian income tax purposes.
Major Estimate Revision • Oct 26Consensus forecasts updatedThe consensus outlook for 2023 has been updated. 2023 EPS estimate increased from CA$0.19 to CA$0.27. Revenue forecast steady at CA$749.4m. Net income forecast to grow 53% next year vs 0.4% growth forecast for Consumer Retailing industry in Canada. Consensus price target broadly unchanged at CA$29.30. Share price rose 13% to CA$22.86 over the past week.
공고 • Oct 26+ 1 more updateNeighbourly Pharmacy Inc. (TSX:NBLY) acquired Assets of a Retail Pharmacy Located in Manitoba.Neighbourly Pharmacy Inc. (TSX:NBLY) acquired Assets of a Retail Pharmacy Located in Manitoba on August 23, 2022. Neighbourly Pharmacy Inc. (TSX:NBLY) completed the acquisition of Assets of a Retail Pharmacy Located in Manitoba on August 23, 2022.
공고 • Oct 25Neighbourly Pharmacy Inc. (TSX:NBLY) entered into a binding agreement to acquire Six Community Pharmacies Located in New Brunswick and Nova Scotia.Neighbourly Pharmacy Inc. (TSX:NBLY) entered into a binding agreement to acquire Six Community Pharmacies Located in New Brunswick and Nova Scotia on October 24, 2022. In a related tramsaction the Neighbourly Pharmacy Inc. also entered into a binding agreement to acquire two community pharmacies located in British Columbia. The total purchase price for the Acquisitions is $15.5 million. The Acquisitions will be funded from cash on hand and drawings on the Company’s credit facility. The transaction pending customary regulatory approvals and the satisfaction of customary closing conditions and expected to close by the end of November 2022.
Major Estimate Revision • Oct 22Consensus forecasts updatedThe consensus outlook for 2023 has been updated. 2023 EPS estimate increased from CA$0.19 to CA$0.40. Revenue forecast steady at CA$751.0m. Net income forecast to grow 425% next year vs 0.4% growth forecast for Consumer Retailing industry in Canada. Consensus price target broadly unchanged at CA$29.30. Share price was steady at CA$21.01 over the past week.
Buying Opportunity • Oct 18Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be CA$26.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 73% in a year. Earnings is forecast to grow by 425% in the next year.
공고 • Aug 31Neighbourly Pharmacy Inc. Appoints Billy Wong as CFO to Succeed Terri SmythNeighbourly Pharmacy Inc. announced that Terri Smyth will be stepping away from her role as Chief Financial Officer for family reasons as she relocates to British Columbia with her family over the coming months. Ms. Smyth will continue in her capacity as CFO until October 25, 2022, when Neighbourly plans to release its second quarter 2023 financial results. Ms. Smyth continues to be committed to the success and growth of the business and will be remaining with the Company through March 2023, to ensure a seamless and orderly transition. Succeeding Terri Smyth is Billy Wong, a seasoned finance executive with more than 15 years in progressive roles of increased scope and responsibility in forecasting, planning, analysis, decision support and continuous improvement across various retail and consumer companies. Over the last four years, Mr. Wong was Chief Financial Officer at Camuto Group, Chief Financial Officer & Chief Operations Officer at Designer Brands Canada, both divisions of Designer Brands Inc. Prior to that, Mr. Wong was an Executive Vice President, CFO at Sears Canada. Mr. Wong will start at Neighbourly on September 19, 2022 and will work closely with Ms. Smyth over the coming months to ensure a smooth transition into the CFO role. Ms. Smyth will continue to support Mr. Wong through the balance of the fiscal year.
Upcoming Dividend • Aug 22Upcoming dividend of CA$0.045 per shareEligible shareholders must have bought the stock before 29 August 2022. Payment date: 27 September 2022. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 0.9%. Lower than top quartile of Canadian dividend payers (5.4%). Lower than average of industry peers (1.2%).
분석 기사 • Aug 10Neighbourly Pharmacy's (TSE:NBLY) Robust Earnings Are Supported By Other Strong FactorsEven though Neighbourly Pharmacy Inc.'s ( TSE:NBLY ) recent earnings release was robust, the market didn't seem to...
Reported Earnings • Aug 03First quarter 2023 earnings: EPS misses analyst expectationsFirst quarter 2023 results: CA$0.029 loss per share (up from CA$7.50 loss in 1Q 2022). Revenue: CA$114.4m (up 34% from 1Q 2022). Net loss: CA$999.0k (loss narrowed 99% from 1Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 74%, compared to a 7.7% growth forecast for the industry in Canada.
공고 • Aug 03Neighbourly Pharmacy Inc. Declares Dividend on Common Share for the First Quarter Ended June 18, 2022, Payable on September 27, 2022Neighbourly Pharmacy Inc. announced its dividend of $0.045 for each common share for the first quarter ended June 18, 2022. The dividend will be paid on September 27, 2022, to the Company's common shareholders of record as of August 30, 2022.
Upcoming Dividend • Jul 13Upcoming dividend of CA$0.045 per shareEligible shareholders must have bought the stock before 20 July 2022. Payment date: 18 August 2022. The company is not currently making a profit and its cash payout ratio is 76%. Trailing yield: 0.8%. Lower than top quartile of Canadian dividend payers (5.5%). Lower than average of industry peers (1.2%).
공고 • Jun 29Neighbourly Pharmacy Inc. (TSX:NBLY) completed the acquisition of Rubicon Pharmacies Canada Inc.Neighbourly Pharmacy Inc. (TSX:NBLY) entered into a definitive agreement to acquire Rubicon Pharmacies Canada Inc. for approximately CAD 440 million on March 10, 2022. The acquisition is for a Cash purchase price of approximately CAD 440 million. The Acquisition will be partially financed through a CAD 250 million equity issuance of subscription receipts, of which approximately 48% will be purchased on a private placement basis by an affiliate of Persistence Capital Partners, Neighbourly’s largest shareholder, and the balance will be distributed by way of public offering. The balance of the purchase price will be financed through draw downs on the Company’s Restated Credit Facilities and cash on hand. In connection with the Acquisition, affiliates of Scotiabank and RBC provided a commitment letter providing for commitments to replace or amend and restate the Company’s existing credit agreement with the following credit facilities: (a) CAD 200 million revolving credit facility maturing May 25, 2026, (b) an upsized CAD 200 million senior term loan credit facility maturing May 25, 2026, and (c) a new CAD 250 million bridge credit facility. Rubicon generated approximately CAD 303 million of revenue and approximately CAD 39 million of EBITDA during the twelve-month period ended September 30, 2021. The Acquisition has been unanimously approved by the directors of Neighbourly, and remain subject to customary closing conditions, including regulatory approvals. In addition, the conditions to the completion of the Acquisition in the Purchase Agreement include that any ROFR shall have either been extinguished or waived by the applicable ROFR party, or that the transaction pursuant to which the applicable ROFR parties acquired any ROFR Pharmacies shall have been consummated. As of June 7, 2022 Neighbourly Pharmacy Inc. received a "no-action letter" from the Competition Bureau to proceed with its previously announced acquisition of Rubicon Pharmacies. Neighbourly expects the completion of the acquisition to occur on June 27, 2022. The Acquisition is expected to occur during the first quarter of Fiscal 2023 (the second quarter of the calendar year 2022). As of June 23, 2022 the Rubicon Acquisition is expected to close by the end of June 2022. Royal Bank of Canada (TSX:RY) acted as financial advisor to Neighbourly Pharmacy Inc. The Bank of Nova Scotia (TSX:BNS) acted as financial advisor to Neighbourly Pharmacy Inc. Benjamin Bloom, Frank DeLuca, Melodie D. Eng and Marc Senderowitz of Minden Gross LLP acted as legal advisor to Neighbourly Pharmacy Inc. Stikeman Elliott LLP acted as legal advisor to Neighbourly Pharmacy Inc. Guy Berman, Danielle Traub, Justin Crawford, Nick Germanakos, Erica Bird and Jessica Reid (corporate/M&A), Teresa Reguly (food and drug regulatory), Omar Wakil and Ian Li (competition), Tom Stevenson (employment), Andy Gibbons (real estate), Jerald Wortsman and Benjamin Mann (tax) of Torys LLP acted as legal advisors to Rubicon Pharmacies in the transaction. RBC Capital Markets acted as financial advisor to Neighbourly pharmacy. Neighbourly Pharmacy Inc. (TSX:NBLY) completed the acquisition of Rubicon Pharmacies Canada Inc. on June 27, 2022.
Reported Earnings • Jun 25Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: CA$2.57 loss per share (up from CA$199 loss in FY 2021). Revenue: CA$427.5m (up 40% from FY 2021). Net loss: CA$73.4m (loss narrowed 20% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 11%. Over the next year, revenue is forecast to grow 78%, compared to a 6.5% growth forecast for the retail industry in Canada.
Price Target Changed • Jun 24Price target decreased to CA$33.44Down from CA$37.00, the current price target is an average from 9 analysts. New target price is 36% above last closing price of CA$24.54. Stock is down 12% over the past year.
공고 • Jun 24Neighbourly Pharmacy Inc. Announces Quarterly Dividend, Payable on August 18, 2022Neighbourly Pharmacy Inc. announced that a quarterly dividend will be paid on August 18, 2022, to the Company's common shareholders of record as of July 21, 2022. The amount of the dividend will be $0.045 for each common share.
공고 • Jun 06+ 1 more updateNeighbourly Pharmacy Inc. to Report Q1, 2023 Results on Aug 02, 2022Neighbourly Pharmacy Inc. announced that they will report Q1, 2023 results on Aug 02, 2022
공고 • May 27Neighbourly Pharmacy Inc., Annual General Meeting, Aug 02, 2022Neighbourly Pharmacy Inc., Annual General Meeting, Aug 02, 2022.
공고 • May 18Neighbourly Pharmacy Inc. to Report Q4, 2022 Results on Jun 23, 2022Neighbourly Pharmacy Inc. announced that they will report Q4, 2022 results Pre-Market on Jun 23, 2022
Board Change • Apr 27High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Independent Chairman of the Board Stuart Elman is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공고 • Apr 15Neighbourly Pharmacy Inc. announced that it has received CAD 138.163875 million in funding from PCP GP, L.P.On April 14, 2022, Neighbourly Pharmacy Inc. closed the transaction. The company amended the terms of the transaction, and issued 622,500 subscription receipts for gross proceeds of CAD 18,021,375 in its second tranche closing, bringing the total gross proceeds raised in the transaction to CAD 138,163,875.
분석 기사 • Mar 21News Flash: Analysts Just Made A Substantial Upgrade To Their Neighbourly Pharmacy Inc. (TSE:NBLY) ForecastsNeighbourly Pharmacy Inc. ( TSE:NBLY ) shareholders will have a reason to smile today, with the analysts making...
Upcoming Dividend • Mar 07Upcoming dividend of CA$0.045 per shareEligible shareholders must have bought the stock before 14 March 2022. Payment date: 12 April 2022. The company is not currently making a profit and its cash payout ratio is 79%. Trailing yield: 0.6%. Lower than top quartile of Canadian dividend payers (4.8%). Lower than average of industry peers (1.3%).
분석 기사 • Feb 27Is There An Opportunity With Neighbourly Pharmacy Inc.'s (TSE:NBLY) 48% Undervaluation?In this article we are going to estimate the intrinsic value of Neighbourly Pharmacy Inc. ( TSE:NBLY ) by taking the...
Reported Earnings • Feb 16Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: CA$0.03 loss per share (up from CA$245 loss in 3Q 2021). Revenue: CA$139.2m (up 27% from 3Q 2021). Net loss: CA$889.0k (loss narrowed 99% from 3Q 2021). Revenue missed analyst estimates by 2.7%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to grow 38%, compared to a 5.5% growth forecast for the industry in Canada.
공고 • Feb 16+ 2 more updatesNeighbourly Pharmacy Inc. (TSX:NBLY) entered into an agreement to acquire one additional pharmacy in Canada.Neighbourly Pharmacy Inc. (TSX:NBLY) entered into an agreement to acquire one additional pharmacy in Canada on February 15, 2022.
Major Estimate Revision • Feb 13Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -CA$1.41 to -CA$2.12 per share. Revenue forecast of CA$431.9m unchanged since last update. Consumer Retailing industry in Canada expected to see average net income growth of 13% next year. Consensus price target of CA$34.88 unchanged from last update. Share price rose 3.9% to CA$31.84 over the past week.
Upcoming Dividend • Nov 15Upcoming dividend of CA$0.045 per shareEligible shareholders must have bought the stock before 22 November 2021. Payment date: 21 December 2021. Trailing yield: 0.5%. Lower than top quartile of Canadian dividend payers (4.5%). Lower than average of industry peers (1.2%).
Reported Earnings • Oct 27Second quarter 2022 earnings released: CA$0.11 loss per share (vs CA$24.48 loss in 2Q 2021)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2022 results: Revenue: CA$90.7m (down 17% from 2Q 2021). Net loss: CA$3.65m (loss narrowed 97% from 2Q 2021).
Upcoming Dividend • Sep 06Upcoming dividend of CA$0.045 per shareEligible shareholders must have bought the stock before 13 September 2021. Payment date: 12 October 2021. Trailing yield: 0.5%. Lower than top quartile of Canadian dividend payers (4.6%). Lower than average of industry peers (1.3%).
Breakeven Date Change • Aug 05Forecast breakeven pushed back to 2023The 6 analysts covering Neighbourly Pharmacy previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 47% to 2022. The company is expected to make a profit of CA$33.9m in 2023. Average annual earnings growth of 102% is required to achieve expected profit on schedule.
Reported Earnings • Jun 28Full year 2021 earnings released: CA$19.88 loss per share (vs CA$5.08 loss in FY 2020)The company reported a mediocre full year result with increased losses and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: CA$306.5m (up 64% from FY 2020). Net loss: CA$91.3m (loss widened 291% from FY 2020).
공고 • Jun 25+ 2 more updatesNeighbourly Pharmacy Inc. (TSX:NBLY) acquired One Pharmacy in Canada.Neighbourly Pharmacy Inc. (TSX:NBLY) acquired One Pharmacy in Canada on June 22, 2021. Neighbourly Pharmacy Inc. (TSX:NBLY) completed the acquisition of One Pharmacy in Canada on June 22, 2021.
공고 • May 26Neighbourly Pharmacy Inc. has completed an IPO in the amount of CAD 175.015 million.Neighbourly Pharmacy Inc. has completed an IPO in the amount of CAD 175.015 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 10,295,000 Price\Range: CAD 17 Discount Per Security: CAD 1.02 Transaction Features: Regulation S; Rule 144A; Sponsor Backed Offering
